Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Pretreated PDX Model Development Services

Focusing on the development of pretreated patient-derived xenograft (PDX) models, Alfa Cytology is committed to precise model customization and stringent quality control, aiming to more accurately replicate human tumor biology, thereby improving predictive power in preclinical studies.

Research Progress of Pretreated PDX Models

Pretreated PDX models are characterized by their ability to mimic the heterogeneity of human cancers, including genetic, histopathological, and treatment response diversity. These models retain the microenvironmental context of the original tumor, providing a more realistic platform for evaluating therapeutic efficacy and toxicity. In preclinical cancer research, the scope of pretreated PDX models is vast. They are used to investigate the efficacy of new drugs, study drug resistance mechanisms, and test combination therapies. These models are particularly useful for cancers with high relapse rates post-treatment, as they can replicate the scenario of recurrent disease.

Fig. 1 History of PDX Research. Fig.1 The brief timeline of milestones in PDX study. (Liu, Y., et al., 2023)

Our Services

With a well-established technology platform of the tumor microenvironment center, Alfa Cytology provides our clients with one-stop solutions for pretreated PDX model development. Our team of expert scientists can tailor the perfect preclinical efficacy testing strategy for your specific research needs.

Pretreated PDX Models Available

Alfa Cytology provides pretreated PDX models for a wide range of human cancer types, including but not limited to:

Types of Cancer	Pretreated PDX Models Available
Breast Cancer	Estrogen Receptor (ER) Positive Models; HER2-Positive Models; Triple-Negative Breast Cancer (TNBC) Models.
Colorectal Cancer	KRAS Mutant Models; Microsatellite Instability (MSI) Models.
Pancreatic Cancer	Gemcitabine-Resistant Models.
Prostate Cancer	Castration-Resistant Prostate Cancer (CRPC) Models.
Lung Cancer	Non-Small Cell Lung Cancer (NSCLC) Models; Small Cell Lung Cancer (SCLC) Models.

Features of Our Pretreated PDX Models

Alfa Cytology utilizes state-of-the-art technology and expertise to deliver high-quality pretreated PDX models that provide enhanced utility for preclinical cancer research, with key benefits including:

Genetic and Histopathological Fidelity

Genetic, epigenetic and histopathological characteristics of the original patient's tumor are maintained, improving the translatability of preclinical study results.

High Predictive Power

By closely modeling human cancer biology and treatment regimens, these models can reliably predict the efficacy and toxicity of new therapies.

Heterogeneity Representation

The pretreated PDX models encompass the heterogeneity, including intra-tumor and inter-tumor variability, this diversity facilitates the study of different tumor subtypes.

Compatibility with High-Throughput Screening

The high scalability and efficiency of these models allows efficient evaluation of multiple therapeutics and combinations, which accelerates the drug discovery process.

Our Service Process

Workflow of Pretreated PDX Model Development

Tumor Collection and Characterization

Tumor samples are collected from patients and undergo genomic, transcriptomic, and histopathological analyses to ensure accurate representation of the original cancer.

Pretreatment Regimen Application

Design pretreatment programs based on treatment history, including specific medications, dosages, and schedules to replicate patient treatment scenarios.

Xenograft Implantation and Validation

Human tumor tissues are implanted into immunodeficient mice, with subsequent monitoring to confirm successful engraftment and tumor growth.

Therapeutic Testing and Analysis

Novel therapeutic agents and combinations are systematically tested on the pretreated PDX models, with detailed data analysis to evaluate efficacy, toxicity, and resistance mechanisms.

Alfa Cytology provides comprehensive solutions to address key challenges encountered in the field of cancer therapy development. With extensive experience in a wide range of cancer models and expertise in tumors and microenvironments, we are committed to providing our clients with the most accurate in vivo cancer models to meet their precise needs. For inquiries or to learn more about how we can support your cancer research program, please contact us.

Reference

Liu, Y., et al.; (2023). Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction and Targeted Therapy, 8(1), 160.

For research use only.